Status:
COMPLETED
To Evaluate the Effects of Omega 3 Fatty Acids in the Context of Cancer Prevention
Lead Sponsor:
Université Catholique de Louvain
Conditions:
Healthy
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Previous studies have demonstrated, in an in vitro micro-tumour model (the spheroid) and in a mouse model, that long-chain omega-3 fatty acids, in particular docosahexaenoic acid (DHA), can inhibit tu...
Detailed Description
The objective of this study is to collect DHA-enriched human serum in order to test it on the in vitro tumour model, spheroids. The results will be compared with human serum enriched in fatty acids (s...
Eligibility Criteria
Inclusion
- Woman or man, aged of 18 to 65 years;
- Body mass index between 20 and 30 kg/m2;
- For women: use of effective contraception;
- Provision of signed and dated informed consent form;
- Stated willingness to comply with all study procedures and availability for the duration of the study.
Exclusion
- Uncontrolled systolic blood pressure \> 160/100 mmHg;
- For premenopausal women: pregnant women or women planning to get pregnant within 3 months or lactating women;
- For menopausal women: less than 6 months of menopause;
- Type II diabetes (controlled or uncontrolled), Type I diabetes;
- Medical history or actual severe psychiatric, severe neurologic, severe hepatic, severe pancreatic, severe kidney, severe pulmonary, severe cardiovascular or severe gastrointestinal problem;
- Thyroid disorder;
- Cancer \< 3 years before the inclusion;
- Consumption of drug under prescription or over-the-counter drug or dietary supplement (including n-3 PUFA) within 1 month before the inclusion (excepted contraception);
- Consumption of fish or of omega-3 enriched eggs \> 2 times per week within 1 month before the inclusion;
- Subjects who are not able to understand and follow study procedures;
- Drug addiction problem (occasional or regular consumption);
- Women who drink more than 2 glasses of alcohol per day (\> 20 g of alcohol per day or \> 140 g/week) or men who drink more than 3 glasses of alcohol per day (\> 30 g of alcohol per day or more than 210 g/week);
- Subjects having given their blood within less than 3 months before inclusion;
- Subjects having participated to another clinical trial with an investigational product within less than 1 month before the inclusion.
Key Trial Info
Start Date :
February 23 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 21 2021
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT05427604
Start Date
February 23 2021
End Date
June 21 2021
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLouvain - CICN
Louvain-la-Neuve, Belgium, 1348